Tvardi Therapeutics (NASDAQ:TVRD) Stock Rating Upgraded by Wall Street Zen

Tvardi Therapeutics (NASDAQ:TVRD) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Sunday.

Several other analysts have also commented on TVRD. Weiss Ratings restated a “sell (e)” rating on shares of Tvardi Therapeutics in a research report on Monday, December 29th. Lucid Cap Mkts raised shares of Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $55.50.

Tvardi Therapeutics Price Performance

NASDAQ:TVRD opened at $3.98 on Friday. The firm has a market cap of $37.33 million, a price-to-earnings ratio of -0.41 and a beta of 0.13. The company has a 50 day moving average price of $4.07 and a 200-day moving average price of $12.06. Tvardi Therapeutics has a 1-year low of $3.50 and a 1-year high of $43.65.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in TVRD. JPMorgan Chase & Co. acquired a new stake in Tvardi Therapeutics during the 2nd quarter worth $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Tvardi Therapeutics in the second quarter valued at about $43,000. Headlands Technologies LLC acquired a new stake in shares of Tvardi Therapeutics in the second quarter valued at about $80,000. New York State Common Retirement Fund purchased a new position in shares of Tvardi Therapeutics in the second quarter worth about $92,000. Finally, Arax Advisory Partners boosted its position in Tvardi Therapeutics by 277.2% during the fourth quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock worth $36,000 after acquiring an additional 6,173 shares during the last quarter. 44.66% of the stock is owned by institutional investors and hedge funds.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.